National HealthCare director exercises 1,021 options
NATIONAL HEALTHCARE CORP director David R. Gifford reported an option exercise on August 13, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
NATIONAL HEALTHCARE CORP director David R. Gifford reported an option exercise on August 13, 2026. He exercised 1,021 options from a 2026 grant with an exercise price of $171.42 per share, receiving 1,021 shares of common stock. After the transactions, he directly holds 1,021 common shares and 6,479 options from this grant, which was issued under the 2020 Omnibus Equity Incentive Plan and is stated as exempt from Section 16(b) under Rule 16b-3(d).
Insider Trade Summary
1,021 shares exercised/converted
Exercise
2 txns
Insider
Gifford David R.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock [2026 Grant] F1 | 1,021 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,021 | $171.42 | $175K |
Holdings After Transaction:
Option to Purchase Common Stock [2026 Grant] — 6,479 contracts (Direct);
Common Stock — 1,021 shares (Direct)
Footnotes (1)
- F1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
Key Figures
Options exercised: 1,021 shares
Exercise price: $171.42 per share
Common shares after transaction: 1,021 shares
+4 more
7 metrics
Options exercised
1,021 shares
Options to purchase common stock exercised on August 13, 2026
Exercise price
$171.42 per share
Conversion or exercise price for the 2026 option grant
Common shares after transaction
1,021 shares
Directly held common stock following the August 13, 2026 exercise
Remaining options from grant
6,479 options
Options to purchase common stock held after exercising 1,021 options
Underlying option grant size
7,500 options
Total underlying common stock for the 2026 option grant
Option grant date
May 7, 2026
Grant date under the 2020 Omnibus Equity Incentive Plan
Option expiration date
May 6, 2031
Expiration of the 2026 stock option grant
Key Terms
Option to Purchase Common Stock, 2020 Omnibus Equity Incentive Plan, Section 16(b), Rule 16b-3(d)
4 terms
Option to Purchase Common Stock financial
"Security title is listed as "Option to Purchase Common Stock [2026 Grant]""
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan"
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"are exempt from Section 16(b) pursuant to Rule 16b-3(d)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NHC director David R. Gifford report in this Form 4 filing?
David R. Gifford reported exercising 1,021 stock options for NATIONAL HEALTHCARE CORP (NHC) on August 13, 2026, acquiring 1,021 common shares. The options were from a 2026 grant under the 2020 Omnibus Equity Incentive Plan.
At what price were the NHC stock options exercised in this Form 4?
The reported options were exercised at an exercise price of $171.42 per share. This conversion price applied to 1,021 options, resulting in an equal number of common shares, as part of a grant under the 2020 Omnibus Equity Incentive Plan.
What happens to David R. Gifford’s NHC stock options after this reported exercise?
Following the exercise of 1,021 options, 6,479 options from the same 2026 grant remain reported as held. The options, originally granted under the 2020 Omnibus Equity Incentive Plan, carry an expiration date of May 6, 2031.
Were the NHC option transactions in this Form 4 exempt from Section 16(b)?
Yes. The filing notes the stock options were granted on May 7, 2026 under the 2020 Omnibus Equity Incentive Plan and states that the grant and exercise are exempt from Section 16(b) pursuant to Rule 16b-3(d).
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates